Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention

References

• Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 2009;104:227–233.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O’Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ENDEAVOR III Investigators. Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease. A Randomized Controlled Trial. J Am Coll Cardiol 2006;48:2440–2447.
   PubMed Web of Science ®Google Scholar
• Can MM, Tanboğa IH, Türkyilmaz E, Karabay CY, Akgun T, Koca F, Tokgoz HC, Keles N, Ozkan A, Bezgin T, Ozveren O, Sonmez K, Sağlam M, Ozdemir N, Kaymaz C. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res 2010;125:e132–e137.
   PubMed Web of Science ®Google Scholar
• Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin 10 generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617–624.
   PubMed Web of Science ®Google Scholar
• Al Dieri R, Alban S, Beguin S, Hemker H. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004;2:1395–1401.
   PubMed Web of Science ®Google Scholar
• Al Dieri R, Alban S, Beguin S, Hemker H. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 2006;4:83–89.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007;5:955–962.
   PubMed Web of Science ®Google Scholar
• Stief TW. Inhibition of thrombin generation in recalcified plasma. Blood Coagul Fibrinolysis 2007;18:751–760.
   PubMed Web of Science ®Google Scholar
• Altman R, Scazziota A, Herrera L, González C. Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy. J Thromb Haemost 2007;5:1552–1569.
   PubMed Web of Science ®Google Scholar
• Jackson CM, Esnouf MP, Lindahl TL. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 2003;33:43–51.
   PubMedGoogle Scholar
• Gatt A, Veen J van, Bowyer A, Cooper P, Kitchen S, Resch M. Significant variation in thrombin generation potential in ‘adequately’ anticoagulated patients. J Thromb Haemost 2007;5 (Suppl.S2): P–M–097.(Abstract)
   Google Scholar
• Altman R, Scazziota A, Santoro S, Gonzalez C. Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor. Clin Appl Thromb Hemost 2005;11:271–277.
   PubMed Web of Science ®Google Scholar
• Altman R, Scazziota A, Lourdes Herrera M DE, Gonzalez C. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006;4:2022–2027.
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, Dieri R Al, Regnault V, Smedt E de, Wagenvoord R, Lecompte T, Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4–15.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010;31:17–28.
   PubMed Web of Science ®Google Scholar
• Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery. Eur J Cardiothorac Surg 2014;46:517–592.
   Google Scholar
• Cassimatis DC, Wenger NK. America vs Europe and the 2014 Non-ST Elevation Acute Coronary Syndrome Guidelines. J Cardiovasc Transl Res 2015;8:385–391.
   PubMed Web of Science ®Google Scholar
• Yang H, Kim A, David T, Palmer D, Jin T, Tien J, Huang F, Cheng T, Coughlin SR, Jan YN, Jan LY. TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell 2012;151:111–122.
   PubMed Web of Science ®Google Scholar
• Vanschoonbeek K, Feijge MAH, Keuren JFW, Coenraad Hemker H, Lodder JJ, Hamulyák K, Pampus ECM van, Heemskerk JWM. Thrombin-induced hyperactivity of platelets of young stroke patients: involvement of thrombin receptors in the subject-dependent variability in Ca2+ signal generation. Thromb Haemost 2002;88:931–937.
   Google Scholar
• Vanschoonbeek K, Feijge MAH, Kampen RJW Van, Kenis H, Hemker HC, Giesen PLA, Heemskerk JWM. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004;2:476–484.
   PubMed Web of Science ®Google Scholar
• Meijden PEJ van der, Feijge MAH, Giesen PLA, Huijberts M, Raak LPM van, Heemskerk JWM. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 2005;93:1128–1136.
   PubMed Web of Science ®Google Scholar
• Muller O, Bartunek J, Hamilos M, Berza CT, Mangiacapra F, Ntalianis A, Vercruysse K, Duby C, Wijns W, De Bruyne B, Heyndrickx GR, Vanderheyden M, Holz JB, Barbato E. von Willebrand factor inhibition improves endothelial function in patients with stable angina. J Cardiovasc Transl Res 2013;6:364–370.
   PubMed Web of Science ®Google Scholar
• Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll Cardiol 2013;61:2115–2129.
   PubMed Web of Science ®Google Scholar
• Borissoff JI, Spronk HMH, Heeneman S, ten Cate H. Is thrombin a key player in the ‘coagulation-atherogenesis’ maze? Cardiovasc Res 2009;82:392–403.
   PubMed Web of Science ®Google Scholar
• Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011;364:1746–1760.
   PubMed Web of Science ®Google Scholar
• Attanasio M, Marcucci R, Gori AM, Paniccia R, Valente S, Balzi D, Barchielli A, Carrabba N, Valenti R, Antoniucci D, Abbate R, Gensini GF. Residual thrombin potential predicts cardiovascular death in acute coronarysyndrome patients undergoing percutaneous coronary intervention. Thromb Res 2016;147:52–57.
   PubMed Web of Science ®Google Scholar
• Valente-Acosta B, Baños-González MA, Peña-Duque MA, Martínez-Ríos MA, Quintanar-Trejo L, Aptilon-Duque G, Flores-García M, Cruz-Robles D, Cardoso-Saldaña G, de la Peña-Díaz A. Association between stable coronary artery disease and in vivo thrombin generation. Cardiol Res Pract 2016. Epub 2016 Aug 11. doi:10.1155/2016/5149825
   Google Scholar
• Kamphuisen PW. Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment. Eur Heart J 2008;29:1699–700.
   PubMed Web of Science ®Google Scholar
• Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993;92:2003–2012.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Bayer G, Bergmeister H, Quehenberger P, Petzelbauer P, Friedl P, Mesteri I, Jilma B. An experimental model to study isolated effects of thrombin in vivo. Thromb Res 2010;126:454–461.
   PubMed Web of Science ®Google Scholar
• Jovanovic L, Antonijevic N, Novakovic T, Savic N, Terzic B, Zivkovic I, Radovanovic N, Asanin M. Practical aspects of monitoring of antiplatelet therapy. Semin Thromb Hemost 2017;43:14–23.
   Google Scholar
• Yao Y, Zhang JH, Tang XF, He C, Ma YL, Xu JJ, Song Y, Liu R, Meng XM, Song L, Wang M, Gao RL, Yuan JQ. Head to head comparison of two point-of-care platelet function tests used for assessment of on-clopidogrel platelet reactivity in chinese acute myocardial infarction patients undergoing percutaneous coronary intervention. Chin Med J (Engl) 2016;129:2269–2274.
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M. Platelet function tests. Semin Thromb Hemost 2016;42:258–267.
   PubMed Web of Science ®Google Scholar
• Bagoly Z, Homoródi N, Kovács EG, Sarkady F, Csiba L, Édes I, Muszbek L. How to test the effect of aspirin and clopidogrel in patients on dual antiplatelettherapy? Platelets 2016;27:59–65.
   PubMed Web of Science ®Google Scholar
• Karathanos A, Geisler T. Monitoring aspirin and clopidogrel response: testing controversies and recommendations. Mol Diagn Ther 2013;17:123–37.
   PubMed Web of Science ®Google Scholar